{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:15:06Z","timestamp":1790190906274,"version":"4.1.0"},"reference-count":55,"publisher":"Harborside Press, LLC","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p>Patients with relapsed or refractory multiple myeloma (RRMM) that is refractory to a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-CD38 antibody (triple-class refractory MM) have poor outcomes. Recently, 2 classes of T-cell engaging therapies\u2014CAR T-cell therapy and bispecific T-cell engaging antibodies (BsAbs)\u2014have resulted in unprecedented response rates and survival outcomes in these heavily pretreated patients. The most common targets are BCMA and GPRC5D, with other targets in development. The main classes of adverse effects include cytokine release syndrome, neurotoxicity, infections, and cytopenias, as well as adverse effects unique to specific products. As of September 2023, 2 BCMA-targeting CAR-T cell products, 2 BCMA-targeting BsAbs, and 1 GPRC5D-targeting BsAb, are FDA-approved for standard-of-care use in patients with RRMM who received at least 4 prior lines of therapy, including prior treatment with a proteasome inhibitor, an IMiD, and an anti-CD38 antibody. Earlier-line use is under investigation and has shown promising results. Several other investigational CAR-T constructs and bispecific antibodies are in clinical development. As these therapies become more widely used, including in earlier-line setting, efforts to understand optimal sequencing and mitigate toxicities remain critical.<\/jats:p>","DOI":"10.6004\/jnccn.2023.7100","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T20:49:16Z","timestamp":1702327756000},"page":"1303-1311","source":"Crossref","is-referenced-by-count":9,"title":["Integrating Immune Therapies for the Treatment of Multiple Myeloma"],"prefix":"10.6004","volume":"21","author":[{"given":"Lekha","family":"Mikkilineni","sequence":"first","affiliation":[{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Nat Rev Clin Oncol","first-page":"409","article-title":"The multiple myelomas \u2013 current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar SK","year":"2018","unstructured":"Kumar SK, Rajkumar SV. The multiple myelomas \u2013 current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol 2018;15:409\u2013421."},{"key":"B2","series-title":"Leukemia","first-page":"2266","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi UH","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A,  Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 2019;33:2266\u20132275."},{"key":"B3","series-title":"N Engl J Med","first-page":"495","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau P","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NW,  Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022;387:495\u2013505."},{"key":"B4","series-title":"Lancet","first-page":"314","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja JG","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ,  Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 2021;398:314\u2013324."},{"key":"B5","series-title":"N Engl J Med","first-page":"1726","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje N","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y,  Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 2019;380:1726\u20131737."},{"key":"B6","series-title":"N Engl J Med","first-page":"335","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel J","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K,  Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med 2023;389:335\u2013347."},{"key":"B7","series-title":"N Engl J Med","first-page":"1002","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero P","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B,  Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 2023;388:1002\u20131014."},{"key":"B8","series-title":"N Engl J Med","first-page":"705","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi NC","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N,  Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021;384:705\u2013716."},{"key":"B9","series-title":"Nat Rev Clin Oncol","first-page":"370","article-title":"Driving CAR T-cells forward","volume":"13","author":"Jackson HJ","year":"2016","unstructured":"Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol 2016;13:370\u2013383."},{"key":"B10","series-title":"Nat Rev Clin Oncol","first-page":"418","article-title":"T cell-engaging therapies \u2013 BiTEs and beyond","volume":"17","author":"Goebeler ME","year":"2020","unstructured":"Goebeler ME, Bargou RC. T cell-engaging therapies \u2013 BiTEs and beyond. Nat Rev Clin Oncol 2020;17:418\u2013434."},{"key":"B11","series-title":"Nature","first-page":"423","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain M","year":"2017","unstructured":"Sadelain M, Rivi\u00e8re I, Riddell S. Therapeutic T cell engineering. Nature 2017;545:423\u2013431."},{"key":"B12","series-title":"Clin Cancer Res","first-page":"2048","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter RO","year":"2013","unstructured":"Carpenter RO, Evbuomwan MO, Pittaluga S,  B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res 2013;19:2048\u20132060."},{"key":"B13","series-title":"Leukemia","first-page":"985","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah N","year":"2020","unstructured":"Shah N, Chari A, Scott E,  B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 2020;34:985\u20131005."},{"key":"B14","series-title":"J Clin Oncol","first-page":"2267","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno JN","year":"2018","unstructured":"Brudno JN, Maric I, Hartman SD,  T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol 2018;36:2267\u20132280."},{"key":"B15","series-title":"Blood","article-title":"T cells expressing an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor with a fully-human heavy-chain-only antigen recognition domain induce remissions in patients with relapsed multiple myeloma","volume":"134","author":"Mikkilineni L","year":"2019","unstructured":"Mikkilineni L, Manasanch EE, Lam N,  T cells expressing an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor with a fully-human heavy-chain-only antigen recognition domain induce remissions in patients with relapsed multiple myeloma. Blood 2019;134(Suppl 1):Abstract 704."},{"key":"B16","series-title":"N Engl J Med","first-page":"1196","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody S","year":"2022","unstructured":"Mailankody S, Devlin SM, Landa J,  GPRC5D-targeted CAR T cells for myeloma. N Engl J Med 2022;387:1196\u20131206."},{"key":"B17","series-title":"N Engl J Med","first-page":"2232","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari A","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG,  Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 2022;387:2232\u20132244."},{"key":"B18","series-title":"Sci Transl Med","first-page":"eaau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith EL","year":"2019","unstructured":"Smith EL, Harrington K, Staehr M,  GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med 2019;11:eaau7746."},{"key":"B19","series-title":"Cancer Cell","first-page":"383","article-title":"Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing","volume":"31","author":"Li J","year":"2017","unstructured":"Li J, Stagg NJ, Johnston J,  Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing. Cancer Cell 2017;31:383\u2013395."},{"key":"B20","series-title":"Gene Ther","first-page":"560","article-title":"CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma","volume":"28","author":"Prommersberger S","year":"2021","unstructured":"Prommersberger S, Reiser M, Beckmann J,  CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma. Gene Ther 2021;28:560\u2013571."},{"key":"B21","series-title":"Biol Blood Marrow Transplant","first-page":"625","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee DW","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL,  ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25:625\u2013638."},{"key":"B22","series-title":"Blood Cancer Discov","first-page":"423","article-title":"Bispecific antibodies in multiple myeloma: present and future","volume":"2","author":"Lancman G","year":"2021","unstructured":"Lancman G, Sastow DL, Cho HJ,  Bispecific antibodies in multiple myeloma: present and future. Blood Cancer Discov 2021;2:423\u2013433."},{"key":"B23","series-title":"Curr Med Res Opin","first-page":"81","article-title":"Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma","volume":"39","author":"Martin T","year":"2023","unstructured":"Martin T, Usmani SZ, Schecter JM,  Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin 2023;39:81\u201389."},{"key":"B24","series-title":"Blood","article-title":"Updated results from an ongoing phase 1 clinical study of bb21217 anti-Bcma CAR T cell therapy","volume":"134","author":"Berdeja JG","year":"2019","unstructured":"Berdeja JG, Alsina M, Shah ND,  Updated results from an ongoing phase 1 clinical study of bb21217 anti-Bcma CAR T cell therapy. Blood 2019;134(Suppl 1):Abstract 653."},{"key":"B25","series-title":"Leuk Lymphoma","first-page":"1849","article-title":"Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms","volume":"63","author":"Brudno JN","year":"2022","unstructured":"Brudno JN, Natrakul D, Lam N,  Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms. Leuk Lymphoma 2022;63:1849\u20131860."},{"key":"B26","series-title":"Nat Rev Clin Oncol","first-page":"359","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell KM","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol 2023;20:359\u2013371."},{"key":"B27","series-title":"Blood Cancer J","first-page":"116","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje N","year":"2023","unstructured":"Raje N, Anderson K, Einsele H,  Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J 2023;13:116."},{"key":"B28","series-title":"Semin Hematol","first-page":"52","article-title":"Infectious complications of chimeric antigen receptor (CAR) T-cell therapies","volume":"60","author":"Gea-Banacloche JC","year":"2023","unstructured":"Gea-Banacloche JC. Infectious complications of chimeric antigen receptor (CAR) T-cell therapies. Semin Hematol 2023;60:52\u201358."},{"key":"B29","series-title":"Transplant Cell Ther","first-page":"438.e1","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines MR","year":"2023","unstructured":"Hines MR, Knight TE, McNerney KO,  Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant Cell Ther 2023;29:438.e1\u2013e16."},{"key":"B30","series-title":"J Clin Oncol","first-page":"2087","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen DK","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC,  Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J Clin Oncol 2023;41:2087\u20132097."},{"key":"B31","series-title":"Future Oncol","first-page":"277","article-title":"Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma","volume":"18","author":"Anderson LD Jr","year":"2022","unstructured":"Anderson LD Jr. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. Future Oncol 2022;18:277\u2013289."},{"key":"B32","series-title":"Future Oncol","article-title":"Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed\/refractory multiple myeloma","author":"Martin TG","unstructured":"Martin TG, Madduri D, Pacaud L,  Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed\/refractory multiple myeloma. Future Oncol. Published online July 27, 2023. doi:10.2217\/fon-2022-1317"},{"key":"B33","series-title":"J Hematol Oncol","first-page":"141","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao WH","year":"2018","unstructured":"Zhao WH, Liu J, Wang BY,  A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol 2018;11:141."},{"key":"B34","series-title":"Proc Natl Acad Sci USA","first-page":"9543","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu J","year":"2019","unstructured":"Xu J, Chen LJ, Yang SS,  Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc Natl Acad Sci USA 2019;116:9543\u20139551."},{"key":"B35","series-title":"J Clin Oncol","first-page":"1265","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin T","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG,  Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023;41:1265\u20131274."},{"key":"B36","series-title":"J Clin Oncol","article-title":"CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin Y","year":"2023","unstructured":"Lin Y, Martin TG, Usmani SZ,  CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma. J Clin Oncol 2023;41(Suppl):Abstract 8009."},{"key":"B37","series-title":"Blood Cancer J","first-page":"32","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen AD","year":"2022","unstructured":"Cohen AD, Parekh S, Santomasso BD,  Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J 2022;12:32."},{"key":"B38","series-title":"Nat Med","first-page":"2099","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen O","year":"2021","unstructured":"Van Oekelen O, Aleman A, Upadhyaya B,  Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med 2021;27:2099\u20132103."},{"key":"B39","series-title":"J Clin Oncol","article-title":"Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (cilta-cel) for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Hansen DK","year":"2023","unstructured":"Hansen DK, Patel KK, Peres LC,  Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (cilta-cel) for relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol 2023;41(Suppl):Abstract 8012."},{"key":"B40","series-title":"Nat Med","first-page":"422","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody S","year":"2023","unstructured":"Mailankody S, Matous JV, Chhabra S,  Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med 2023;29:422\u2013429."},{"key":"B41","series-title":"HemaSphere","article-title":"BMS-986393 (CC-95266), a G protein\u2013coupled receptor class C group 5 member D (GPRC5D)\u2013targeted CAR T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): results from a phase 1 study","volume":"7","author":"Bal S","year":"2023","unstructured":"Bal S, Berdeja J, Htut M,  BMS-986393 (CC-95266), a G protein\u2013coupled receptor class C group 5 member D (GPRC5D)\u2013targeted CAR T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): results from a phase 1 study. HemaSphere 2023;7(Suppl 3):Abstract S193."},{"key":"B42","series-title":"Nat Med","first-page":"2259","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin AM","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B,  Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 2023;29:2259\u20132267."},{"key":"B43","series-title":"Blood","article-title":"Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma","volume":"140","author":"Raje N","year":"2022","unstructured":"Raje N, Bahlis NJ, Costello C,  Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma. Blood 2022;140(Suppl 1):Abstract 653."},{"key":"B44","series-title":"N Engl J Med","first-page":"2232","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari A","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG,  Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 2022;387:2232\u20132244."},{"key":"B45","series-title":"Blood","first-page":"219","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen AD","year":"2023","unstructured":"Cohen AD, Mateos MV, Cohen YC,  Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood 2023;141:219\u2013230."},{"key":"B46","series-title":"Blood Cancer J","first-page":"117","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri CJ","year":"2023","unstructured":"Ferreri CJ, Hildebrandt MAT, Hashmi H,  Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J 2023;13:117."},{"key":"B47","series-title":"J Clin Oncol","article-title":"Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents","volume":"40","author":"Touzeau C","year":"2022","unstructured":"Touzeau C, Krishnan AY, Moreau P,  Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents. J Clin Oncol 2022;40(Suppl):Abstract 8013."},{"key":"B48","series-title":"Blood Adv","first-page":"1056","article-title":"Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed\/refractory myeloma","volume":"7","author":"Mouhieddine TH","year":"2023","unstructured":"Mouhieddine TH, Van Oekelen O, Melnekoff DT,  Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed\/refractory myeloma. Blood Adv 2023;7:1056\u20131064."},{"key":"B49","series-title":"J Clin Oncol","article-title":"CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed\/refractory multiple myeloma: updated results of phase 1b\/2 study (FUMANBA-1)","volume":"41","author":"Li C","year":"2023","unstructured":"Li C, Wang D, Song Y,  CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed\/refractory multiple myeloma: updated results of phase 1b\/2 study (FUMANBA-1). J Clin Oncol 2023;41(Suppl):Abstract 8025."},{"key":"B50","series-title":"Blood","first-page":"7435","article-title":"Updated results of Fumanba-1: a phase 1b\/2 study of a novel fully human B-cell maturation antigen-specific CAR T cells (CT103A) in patients with relapsed and\/or refractory multiple myeloma","volume":"140","author":"Li C","year":"2022","unstructured":"Li C, Wang D, Fang B,  Updated results of Fumanba-1: a phase 1b\/2 study of a novel fully human B-cell maturation antigen-specific CAR T cells (CT103A) in patients with relapsed and\/or refractory multiple myeloma. Blood 2022;140(Suppl 1):7435\u20137436."},{"key":"B51","series-title":"Blood","first-page":"7433","article-title":"T cells expressing a fully-human anti-BCMA chimeric antigen receptor with a heavy-chain-only antigen-recognition domain exhibit rapid and durable activity against multiple myeloma","volume":"140","author":"Mikkilineni L","year":"2022","unstructured":"Mikkilineni L, Manasanch EE, Natrakul D,  T cells expressing a fully-human anti-BCMA chimeric antigen receptor with a heavy-chain-only antigen-recognition domain exhibit rapid and durable activity against multiple myeloma. Blood 2022;140(Suppl 1):7433\u20137434."},{"key":"B52","series-title":"Blood Adv","first-page":"768","article-title":"Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma","volume":"7","author":"Frigault MJ","year":"2023","unstructured":"Frigault MJ, Bishop MR, Rosenblatt J,  Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv 2023;7:768\u2013777."},{"key":"B53","series-title":"Blood","first-page":"1360","article-title":"Results from the first phase 1 clinical study of the B-cell maturation antigen (BCMA) nex T chimeric antigen receptor (CAR) T cell therapy CC-98633\/BMS-986354 in patients (pts) with relapsed\/ refractory multiple myeloma (RRMM)","volume":"140","author":"Costa LJ","year":"2022","unstructured":"Costa LJ, Kumar SK, Atrash S,  Results from the first phase 1 clinical study of the B-cell maturation antigen (BCMA) nex T chimeric antigen receptor (CAR) T cell therapy CC-98633\/BMS-986354 in patients (pts) with relapsed\/ refractory multiple myeloma (RRMM). Blood 2022;140(Suppl 1):1360\u20131362."},{"key":"B54","series-title":"J Clin Oncol","article-title":"LINKER-MM1 study: linvoseltamab (REGN5458) in patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lee HC","year":"2023","unstructured":"Lee HC, Bumma N, Richter JR,  LINKER-MM1 study: linvoseltamab (REGN5458) in patients with relapsed\/refractory multiple myeloma. J Clin Oncol 2023;41(Suppl):Abstract 8006."},{"key":"B55","series-title":"J Clin Oncol","first-page":"3576","article-title":"A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D\u2019Souza A","year":"2022","unstructured":"D\u2019Souza A, Shah N, Rodriguez C,  A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma. J Clin Oncol 2022;40:3576\u20133586."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/12\/article-p1303.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/21\/12\/article-p1303.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/21\/12\/article-p1303.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T20:52:52Z","timestamp":1702327972000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/12\/article-p1303.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":55,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2023.7100","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}